Structure Therapeutics is trading at $27.78, down 4.14%, with no clear company-specific catalyst identified for the October 2, 2026 decline.

  • Reports pointed to rival obesity-drug developments and a broader biotech pullback, but did not establish either as the cause of today’s move.
  • Major indexes were higher after weaker-than-expected jobs data eased rate-hike concerns, making broad-market weakness an unlikely explanation.